Overall, the studies evaluating STAT3 inhibitors for OSCC/HNSCC and GC at pre-clinical and early clinical trial stages suggest that it is unlikely that they will be used as a monotherapy. Here, STAT3 is linked to head and neck squamous cell carcinoma.